339 related articles for article (PubMed ID: 32042331)
1. Molecular imaging biomarkers for immune checkpoint inhibitor therapy.
van de Donk PP; Kist de Ruijter L; Lub-de Hooge MN; Brouwers AH; van der Wekken AJ; Oosting SF; Fehrmann RS; de Groot DJA; de Vries EG
Theranostics; 2020; 10(4):1708-1718. PubMed ID: 32042331
[TBL] [Abstract][Full Text] [Related]
2. Programmed Cell Death-1/Ligand-1 PET Imaging: A Novel Tool to Optimize Immunotherapy?
Verhoeff SR; van den Heuvel MM; van Herpen CML; Piet B; Aarntzen EHJG; Heskamp S
PET Clin; 2020 Jan; 15(1):35-43. PubMed ID: 31735300
[TBL] [Abstract][Full Text] [Related]
3. The Future of Cancer Diagnosis, Treatment and Surveillance: A Systemic Review on Immunotherapy and Immuno-PET Radiotracers.
Liberini V; Laudicella R; Capozza M; Huellner MW; Burger IA; Baldari S; Terreno E; Deandreis D
Molecules; 2021 Apr; 26(8):. PubMed ID: 33920423
[TBL] [Abstract][Full Text] [Related]
4. Positron emission tomography molecular imaging to monitor anti-tumor systemic response for immune checkpoint inhibitor therapy.
Xing X; Zhao Q; Zhou J; Zhou R; Liu Y; Qin X; Zhang M; Zhong Y; Wang J; Tian M; Zhang H
Eur J Nucl Med Mol Imaging; 2023 May; 50(6):1671-1688. PubMed ID: 36622406
[TBL] [Abstract][Full Text] [Related]
5. CD4
Kristensen LK; Fröhlich C; Christensen C; Melander MC; Poulsen TT; Galler GR; Lantto J; Horak ID; Kragh M; Nielsen CH; Kjaer A
Theranostics; 2019; 9(26):8221-8238. PubMed ID: 31754392
[TBL] [Abstract][Full Text] [Related]
6. PET/CT molecular imaging in the era of immune-checkpoint inhibitors therapy.
Gao Y; Wu C; Chen X; Ma L; Zhang X; Chen J; Liao X; Liu M
Front Immunol; 2022; 13():1049043. PubMed ID: 36341331
[TBL] [Abstract][Full Text] [Related]
7. Molecular Imaging for Cancer Immunotherapy: Seeing Is Believing.
Saeed M; Xu Z; De Geest BG; Xu H; Yu H
Bioconjug Chem; 2020 Feb; 31(2):404-415. PubMed ID: 31951380
[TBL] [Abstract][Full Text] [Related]
8. Imaging-based Biomarkers for Predicting and Evaluating Cancer Immunotherapy Response.
Wu M; Zhang Y; Zhang Y; Liu Y; Wu M; Ye Z
Radiol Imaging Cancer; 2019 Nov; 1(2):e190031. PubMed ID: 33778682
[TBL] [Abstract][Full Text] [Related]
9. Molecular imaging to enlighten cancer immunotherapies and underlying involved processes.
van der Veen EL; Bensch F; Glaudemans AWJM; Lub-de Hooge MN; de Vries EGE
Cancer Treat Rev; 2018 Nov; 70():232-244. PubMed ID: 30308466
[TBL] [Abstract][Full Text] [Related]
10. The role of PET molecular imaging in immune checkpoint inhibitor therapy in lung cancer: Precision medicine and visual monitoring.
Yao Y; Zhou X; Zhang A; Ma X; Zhu H; Yang Z; Li N
Eur J Radiol; 2022 Apr; 149():110200. PubMed ID: 35158214
[TBL] [Abstract][Full Text] [Related]
11. Glucose-Thymidine Ratio as a Metabolism Index Using
Oh S; Youn H; Paeng JC; Kim YH; Lee CH; Choi H; Kang KW; Chung JK; Cheon GJ
Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012530
[TBL] [Abstract][Full Text] [Related]
12. Molecular imaging to support cancer immunotherapy.
van de Donk PP; Oosting SF; Knapen DG; van der Wekken AJ; Brouwers AH; Lub-de Hooge MN; de Groot DA; de Vries EG
J Immunother Cancer; 2022 Aug; 10(8):. PubMed ID: 35922089
[TBL] [Abstract][Full Text] [Related]
13. Molecular imaging in immuno-oncology: current status and translational perspectives.
Filippi L; Nervi C; Proietti I; Pirisino R; Potenza C; Martelli O; Equitani F; Bagni O
Expert Rev Mol Diagn; 2020 Dec; 20(12):1199-1211. PubMed ID: 33215963
[No Abstract] [Full Text] [Related]
14. Molecular imaging of immune checkpoints in oncology: Current and future applications.
Ge S; Jia T; Li J; Zhang B; Deng S; Sang S
Cancer Lett; 2022 Nov; 548():215896. PubMed ID: 36041658
[TBL] [Abstract][Full Text] [Related]
15. Update on tumor metabolism and patterns of response to immunotherapy.
Castello A; Lopci E
Q J Nucl Med Mol Imaging; 2020 Jun; 64(2):175-185. PubMed ID: 32107904
[TBL] [Abstract][Full Text] [Related]
16. Robust Prediction of Immune Checkpoint Inhibition Therapy for Non-Small Cell Lung Cancer.
Jiang J; Jin Z; Zhang Y; Peng L; Zhang Y; Zhu Z; Wang Y; Tong D; Yang Y; Wang J; Yang Y; Xiao K
Front Immunol; 2021; 12():646874. PubMed ID: 33927719
[TBL] [Abstract][Full Text] [Related]
17. Application of molecular imaging technology in tumor immunotherapy.
Meng Y; Sun J; Qv N; Zhang G; Yu T; Piao H
Cell Immunol; 2020 Feb; 348():104039. PubMed ID: 32007223
[TBL] [Abstract][Full Text] [Related]
18. T-cell functionality testing is highly relevant to developing novel immuno-tracers monitoring T cells in the context of immunotherapies and revealed CD7 as an attractive target.
Mayer KE; Mall S; Yusufi N; Gosmann D; Steiger K; Russelli L; Bianchi HO; Audehm S; Wagner R; Bräunlein E; Stelzl A; Bassermann F; Weichert W; Weber W; Schwaiger M; D'Alessandria C; Krackhardt AM
Theranostics; 2018; 8(21):6070-6087. PubMed ID: 30613283
[TBL] [Abstract][Full Text] [Related]
19. The Tumor Microenvironment in the Response to Immune Checkpoint Blockade Therapies.
Petitprez F; Meylan M; de Reyniès A; Sautès-Fridman C; Fridman WH
Front Immunol; 2020; 11():784. PubMed ID: 32457745
[TBL] [Abstract][Full Text] [Related]
20. Imaging the Cancer Immune Environment and Its Response to Pharmacologic Intervention, Part 2: The Role of Novel PET Agents.
Iravani A; Hicks RJ
J Nucl Med; 2020 Nov; 61(11):1553-1559. PubMed ID: 32887755
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
